Vertex execs sold $1.3M in stock Feb. 25, 2026, amid slight earnings miss and modest insider selling.

On February 25, 2026, multiple Vertex Pharmaceuticals executives, including EVP Duncan McKechnie, sold shares totaling around $1.3 million, with McKechnie’s sale of 1,846 shares reducing his stake by 3.22%. The company reported Q4 earnings of $5.03 EPS, slightly below expectations, and $3.19 billion in revenue, up 9.5% year-over-year. Despite the minor miss and insider selling totaling roughly $4.6 million, fundamentals remain strong, with a $121.97 billion market cap, strong R&D momentum, and a "Moderate Buy" analyst consensus. The stock closed at $480.13, down $2.92, with below-average volume.